Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential
Clear Street has upgraded Korro Bio Inc. (NASDAQ:KRRO) from Hold to Buy and raised its price target to $18 from $10, based on the potential of its new hyperammonemia program, KRRO-121. The firm believes this program addresses an unmet medical need with strong scientific backing, offering a favorable risk/reward profile at current trading levels. This upgrade follows similar positive revisions from other analysts, although some firms maintain a Market Perform rating, acknowledging remaining clinical de-risking and past program setbacks.
Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential
Clear Street upgraded Korro Bio Inc. (NASDAQ:KRRO) to Buy from Hold, raising its price target to $18.00, following an analyst day that highlighted KRRO-121, a new lead program for hyperammonemia. The firm sees strong scientific rationale and significant value potential by 2027, despite remaining clinical risks. Other analysts, including H.C. Wainwright, Piper Sandler, and Chardan Capital Markets, also upgraded Korro Bio, focusing on the promise of KRRO-121, which is expected to enter clinical trials late in 2026.
William Blair Upgrades Korro Bio (KRRO)
William Blair has upgraded Korro Bio (KRRO) from Market Perform to Outperform. The average one-year price target for KRRO is $17.34, suggesting a 55.24% upside from its last closing price. Institutional ownership in Korro Bio shows increased shares, indicating a bullish outlook.
Korro Bio (NASDAQ:KRRO) Upgraded to "Outperform" at William Blair
William Blair has upgraded Korro Bio (NASDAQ:KRRO) from "market perform" to "outperform." Despite mixed analyst sentiment and a consensual "Hold" rating with an average $66.50 price target, the stock opened at $11.17 and has a market cap of approximately $105.2 million. Institutional investors hold about 13.18% of the shares.
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of "Hold" by Brokerages
Korro Bio, Inc. (NASDAQ:KRRO) has received an average "Hold" rating from ten brokerages, with an average 12-month target price of $66.50. Despite beating earnings and revenue expectations in its last quarter, the company remains unprofitable. Institutional ownership has increased, with several firms acquiring new or larger stakes in the biotech company.
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)
H.C. Wainwright has identified KRRO-121 as a significant independent value driver for Korro Bio, Inc. (KRRO). This highlights the potential of the drug in the company's portfolio beyond other pipeline assets. Further details about KRRO-121's progress and market potential would be critical for investors.
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Korro Bio (KRRO) and AstraZeneca (AZN)
Analysts are providing fresh perspectives on several healthcare companies, including Regeneron (REGN), Korro Bio (KRRO), and AstraZeneca (AZN). Regeneron received a "Strong Buy" consensus with a 12.5% upside, Korro Bio a "Moderate Buy" with a 37.2% upside, and AstraZeneca a "Strong Buy" with a 14.7% upside. These ratings come from various analysts like William Pickering of Bernstein, Myles Minter of William Blair, and Graham Parry of Citi, reflecting their assessments of the companies' financial potentials.
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)
H.C. Wainwright has upgraded Korro Bio, Inc. (KRRO) from Neutral to Buy with a $20 price target, highlighting KRRO-121 as an independent and significant value driver. Chardan Capital also upgraded KRRO to Buy with a $15 price target, citing strong preclinical data for KRRO-121. The biopharmaceutical company uses its OPERA platform to develop RNA-editing therapies.
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)
H.C. Wainwright upgraded Korro Bio, Inc. (KRRO) from Neutral to Buy with a $20 price target, citing KRRO-121 as an independent value driver separate from its KRRO-110 program, especially since KRRO's shares trade near zero enterprise value. Chardan Capital also upgraded KRRO to Buy with a $15 price target due to strong preclinical data for KRRO-121. Korro Bio is a biopharmaceutical company utilizing its OPERA platform to develop RNA-editing therapies.
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE
Korro Bio's Analyst Day highlighted KRRO-121, an RNA-editing candidate aimed at controlling high blood ammonia in urea cycle disorders (UCD) and hepatic encephalopathy (HE). Preclinical data presented showed KRRO-121's ability to reduce ammonia levels by stabilizing glutamine synthetase with minimal RNA editing, and the company plans a first-in-human regulatory submission in H2 2026. Korro Bio estimates a significant market opportunity for KRRO-121 in both UCD and HE, anticipating a less frequent subcutaneous dosing regimen.
Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential
H.C. Wainwright has upgraded Korro Bio Inc. (NASDAQ:KRRO) to a Buy rating with a $20 price target, following the unveiling of its new RNA editing drug, KRRO-121, designed for liver-targeted treatment. The upgrade is based on promising preclinical data showing repeatable ammonia reductions and high liver-selective uptake, indicating significant de-risking for a new independent development path. This positive outlook is echoed by other firms like Piper Sandler, Chardan Capital Markets, and Cantor Fitzgerald, despite the company's cash-burn rate, with the new drug showing potential for significant market impact.
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential By Investing.com
Chardan Capital Markets has upgraded Korro Bio Inc. from Neutral to Buy, setting a price target of $15.00 due to the potential of its KRRO-121 program. This upgrade follows Korro's strategic shift to KRRO-121, set to enter clinical trials in late 2026, after previous setbacks. The firm highlights KRRO-121's use of GalNAc conjugation for delivery and its potential to address urea cycle disorder.
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades
Korro Bio (KRRO) received significant analyst upgrades, including a 'Buy' rating from H.C. Wainwright and an 'Overweight' from Piper Sandler, driven by confidence in its drug candidate KRRO-121. The news led to a 13% jump in stock price and a shift to "extremely bullish" sentiment on Stocktwits. Korro plans to file for KRRO-121 clinical trials in mid-2026 for hyperammonemia treatment, leveraging its RNA editing technology.
HC Wainwright Upgrades Korro Bio to Buy From Neutral, Price Target is $20
HC Wainwright has upgraded Korro Bio (KRRO) from Neutral to Buy, setting a new price target of $20. This positive analyst action reflects increased confidence in the biopharmaceutical company, which focuses on genetic medicines using RNA editing for various diseases. The upgrade follows a period of notable analyst activity surrounding Korro Bio.
Piper Sandler upgrades Korro Bio stock rating to Overweight on UCD treatment
Piper Sandler upgraded Korro Bio Inc. (NASDAQ:KRRO) to Overweight with a raised price target of $30.00 following the company's Virtual Analyst Day, where Korro Bio introduced KRRO-121 for Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE). The upgrade, along with similar actions from Chardan Capital Markets and Cantor Fitzgerald, is based on promising preclinical data and significant market opportunities for KRRO-121, despite the company's prior program setbacks. Korro Bio plans to file an Investigational New Drug (IND) application for KRRO-121 in the second half of 2026.
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential
Chardan Capital Markets has upgraded Korro Bio Inc. (NASDAQ:KRRO) stock from Neutral to Buy, increasing its price target to $15.00, due to the company's new focus on KRRO-121. This decision follows positive preclinical data and a strategic shift after previous setbacks, with KRRO-121 expected to enter clinical trials in late 2026. The upgrade aligns with other positive analyst reviews and highlights the potential of Korro's ADAR RNA editing platform, particularly for urea cycle disorders.
Raymond James reiterates Market Perform rating on Korro Bio stock
Raymond James has reiterated its "Market Perform" rating on Korro Bio Inc. (NASDAQ:KRRO), a clinical-stage biopharmaceutical company. The report highlights the potential of Korro's KRRO-121 treatment for Urea Cycle Disorder (UCD), noting promising in vitro and mouse model study results that suggest it could significantly improve ammonia clearance and potentially allow diet liberalization for patients. Despite the positive outlook on KRRO-121's development, the company faces financial challenges, burning through cash with negative EBITDA, and is not expected to be profitable this year, though sales growth is anticipated.
Oppenheimer Upgrades Korro Bio (KRRO)
Oppenheimer has upgraded Korro Bio (KRRO) from Perform to Outperform, with an average one-year price target of $45.90/share, suggesting a significant upside. Despite a projected 100% decrease in annual revenue, institutional ownership of KRRO increased by 1.67% in the last quarter, with several key firms holding substantial shares. The put/call ratio of 5.38 indicates a bearish outlook among options traders.
Cantor Fitzgerald upgrades Korro Bio stock to Overweight on UCD program
Cantor Fitzgerald upgraded Korro Bio Inc. (NASDAQ:KRRO) from Neutral to Overweight with a price target of $21.00, citing its new lead program KRRO-121 for urea cycle disorders. The upgrade is based on preclinical data, clinical strategy, market opportunity, and strong liquidity, despite the company burning through cash. Korro Bio plans to initiate its first-in-human trial in the second half of 2026.
Raymond James reiterates Market Perform rating on Korro Bio stock
Raymond James has reiterated a Market Perform rating on Korro Bio Inc. (NASDAQ:KRRO) due to promising preclinical data for its KRRO-121 treatment, aimed at urea cycle disorders. Despite the stock's year-to-date gains, it has experienced a significant decline over the past year, and analysts do not expect profitability this year although sales growth is anticipated. Other firms like Cantor Fitzgerald, Clear Street, Jones Trading, and William Blair have also provided updated ratings and price targets, highlighting the company's focus on advancing its lead program.
William Blair reiterates Market Perform rating on Korro Bio stock
William Blair has reiterated its Market Perform rating on Korro Bio Inc. (NASDAQ:KRRO) following the presentation of preclinical data for its KRRO-121 program. While the firm views KRRO-121's data as an "incremental positive," especially after the failure of KRRO-110, it maintains a Market Perform rating due to the early stage of the pipeline and the need for significant capital raises, with clinical data not expected until 2027.
Clear Street raises Korro Bio stock price target to $10 on new lead program
Clear Street raised its price target for Korro Bio Inc. to $10 from $7, while maintaining a Hold rating, following the company's Analyst Day where the new lead preclinical program KRRO-121 was discussed. This program targets hyperammonemia in urea cycle disorders and hepatic encephalopathy. Despite the positive adjustment due to the new program, Korro Bio has recently faced setbacks with its KRRO-110 therapy, leading to multiple analyst downgrades.
Korro Bio Showcases KRRO-121 RNA Editing Program Progress
Korro Bio held an Analyst Day to present KRRO-121, a liver-targeted RNA-editing therapy designed to stabilize glutamine synthetase (GS) and improve ammonia clearance. Preclinical data indicates its potential as a first-in-class treatment for urea cycle disorders and other ammonia-driven diseases. The company plans a regulatory filing in the second half of 2026 to initiate first-in-human trials, while TipRanks’ AI Analyst, Spark, rates KRRO as "Neutral" due to ongoing losses and weak technicals.
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment
Korro Bio, Inc. has introduced KRRO-121 as a promising, potential first-in-class treatment for ammonia control in urea cycle disorders (UCD). The company revealed this during its virtual Analyst Day on January 27, 2026, highlighting the drug's ability to enable dietary liberalization for UCD patients. Regulatory filing for first-in-human trials is anticipated in the second half of 2026, supported by robust preclinical data demonstrating effective ammonia clearance.
Parent and liver doctor join Korro Bio to explain ammonia-driven diseases
Korro Bio (Nasdaq: KRRO) will host a virtual Analyst Day on January 27, 2026, to discuss its development of KRRO-121 for hyperammonemia, featuring management, a hepatologist, and a caregiver. The company will present preclinical data supporting a first-in-human trial regulatory filing in H2 2026 and highlight progress in its GalNAc AATD program, which achieved over 90% in vivo RNA editing. This event aims to raise awareness of ammonia-driven diseases and detail Korro's RNA editing pipeline advancements.
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Hold" from Analysts
Korro Bio, Inc. (NASDAQ:KRRO) has received an average "Hold" recommendation from ten analysts, with a 12-month average price target of $76.00. The company reported a Q3 EPS of ($1.92), beating estimates, and revenue of $1.09M, also surpassing expectations, but remains unprofitable. Institutional investors have increased their stakes, with prominent firms like JPMorgan, TCG Crossover Management, Polar Capital, and Millennium Management holding significant positions.
Korro Bio CFO takes medical leave, interim officers appointed
Korro Bio's Chief Financial Officer and Treasurer, Nessan Bermingham, has taken a medical leave of absence. The company has appointed its Chief Legal Officer, Osama Hanash, as interim CFO and Treasurer, and current director Andrew Hack as interim Principal Accounting Officer. This move is effective immediately and the company will continue its operations.
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. (Nasdaq: KRRO) announced that its CEO and President, Ram Aiyar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be webcast live, and a replay will be available for 30 days. Korro is a biopharmaceutical company focused on developing genetic medicines based on RNA editing for both rare and prevalent diseases.
Korro Bio enhances executive compensation and retention incentives
Korro Bio is enhancing its executive compensation and retention incentives within certain parameters to align with its ongoing at-the-market offerings. The company aims to ensure its compensation structure remains competitive and directly tied to long-term company performance.
Korro Bio amends employment agreement with Jeffrey Cerio, increases compensation
Korro Bio (NASDAQ:KRRO) has amended its employment agreement with Jeffrey Cerio, effective December 15, 2025, increasing his base salary to $425,000 for 2025 and enhancing severance benefits. Cerio also received a $100,000 cash bonus and an equity grant of 41,902 restricted stock units as part of an employee retention program. These changes come amidst recent analyst downgrades for Korro Bio following disappointing clinical results for its KRRO-110 therapy.
Korro Bio Enhances Executive Compensation and Retention Incentives
Korro Bio has revised the employment agreement for executive Jeffrey Cerio, increasing his annual base salary to $425,000 and improving his severance terms. This move also includes a $100,000 cash bonus and 41,902 restricted stock units, all aimed at enhancing retention and demonstrating appreciation for key leadership. The company's stock, KRRO, is currently rated as a Hold with an $81.00 price target by analysts, while TipRanks' AI Analyst, Spark, rates it as Neutral due to significant R&D costs and reliance on external funding.
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of "Hold" from Analysts
Korro Bio, Inc. (NASDAQ:KRRO) has received an average "Hold" rating from analysts, with a consensus twelve-month price target of $76.00. Despite recent downgrades from several firms, the company beat its quarterly EPS and revenue estimates. Institutional investors have increased their positions in Korro Bio, with hedge funds and other institutions owning 13.18% of the stock.
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today
This article from January 2, 2026, reports on the significant challenges faced by Korro Bio (KRRO), including Novo Nordisk pausing their collaboration, disappointment from KRRO-110, and 34% layoffs. These factors have led to a stock crash and are intended to extend the company's cash runway.
Korro Bio’s RNA Editing Ambitions Take A Hit After Trial Blowup
Korro Bio's shares tanked over 80% after its lead RNA editing drug, KRRO-110, failed to meet targets in early-stage trials, leading to layoffs and a paused partnership with Novo Nordisk. The company's future now largely depends on proving its OPERA platform with new clinical results from other candidates, not expected until at least 2027, amidst significant cash burn and intense competition in the genetic medicines space.
Korro Bio Early Trial Results Fall Short; Stock Hits New Low - Korro Bio (NASDAQ:KRRO)
Korro Bio's stock plummeted after early Phase 1/2a clinical trial results for KRRO-110 in alpha-1 antitrypsin deficiency (AATD) did not achieve projected protein levels, despite demonstrating functional protein production. The company is restructuring, reducing its workforce by approximately a third, and realigning its pipeline to focus on liver-targeting programs, which includes nominating KRRO-121 for hyperammonemia and pausing its collaboration with Novo Nordisk. This led William Blair to downgrade Korro shares from Outperform to Market Perform, citing the non-competitive clinical profile of KRRO-110 and the company's return to a preclinical stage for now.
Korro Bio stock plummets after mixed AATD trial results
Korro Bio Inc. (NASDAQ:KRRO) stock fell 80% after reporting mixed results from its KRRO-110 clinical trial for Alpha-1 Antitrypsin Deficiency (AATD). Although the treatment produced functional protein, it did not achieve the projected levels needed for therapeutic benefit, leading the company to pivot its strategy and announce a 34% workforce reduction. The company also reported a net loss of $18.1 million for the third quarter and the resignation of its Chief Medical Officer.
Korro Bio Pauses Novo Nordisk Collaboration Amid Restructuring
Korro Bio (KRRO) has announced a 12-month pause in its research collaboration and license agreement with Novo Nordisk as part of broader restructuring efforts. The company is reducing its workforce by 34% and has accepted the resignation of its Chief Medical Officer to extend its cash runway and focus on RNA editing programs for liver diseases. An analyst has a "Buy" rating on KRRO stock with a $93.00 price target, while TipRanks’ AI Analyst, Spark, rates it as "Neutral" due to high R&D costs and reliance on external funding.
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial
Korro Bio (KRRO) shares dropped after its early-stage clinical trial for KRRO-110, targeting alpha-1 antitrypsin deficiency, did not meet expectations. The trial found that KRRO-110 failed to achieve the anticipated levels of functional protein after a single dose.
Korro Bio’s Downslide: Crisis or Opportunity?
Korro Bio Inc. (NASDAQ: KRRO) shares have plummeted by -77.78%, reflecting significant investor unease due to challenging financials, including substantial expenses, negative EBIT margins, and a heavy long-term debt burden. The company's experimental drug failing activities and leadership changes, such as Kemi Olugemo’s exit, have further fueled market skepticism, highlighting a critical need for strategic rehabilitation to regain stability and investor confidence. Despite these turbulences, the article explores whether opportunities for innovation and market repositioning could still emerge for Korro Bio.
Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact
Korro Bio is laying off 34% of its workforce after its lead drug candidate, KRRO-110, showed lackluster data, leading to a significant stock drop and a pause in its partnership with Novo Nordisk. The biotech is pivoting its alpha-1 antitrypsin deficiency (AATD) program to a GalNAc-based approach, aiming for clinical trials in 2027, while also focusing on KRRO-121 for hyperammonemia. These measures are intended to extend the company's cash runway into the second half of 2027.
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing
Korro Bio announced a significant restructuring, including layoffs and a shift in its research strategy, after its lead RNA editing drug, KRRO-110, showed disappointing results in early testing for alpha-1 antitrypsin deficiency. The company's shares dropped 80% following the news, and it plans to select a new drug candidate with an improved delivery system next year. This setback puts Korro behind competitors and has led to a pause in its research collaboration with Novo Nordisk.
Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setup
Korro Bio shares plummeted over 75% after disappointing Phase 1/2 trial results for its lead drug KRRO-110 for Alpha-1 Antitrypsin Deficiency, leading to analyst downgrades and a 34% workforce reduction. Despite the setbacks, retail traders on StockTwits view the crash as a potential "buy-the-fear" opportunity, citing the company's cash reserves and a new pipeline candidate. Korro plans to pivot to a new delivery approach for AATD and advance a new therapy for hyperammonemia, extending its cash runway into the second half of 2027.
Korro Bio (Nasdaq: KRRO) cuts workforce 34%, extends cash runway into H2 2027
Korro Bio reported Q3 2025 financial results, announcing a workforce reduction of approximately 34% and extending its cash runway into the second half of 2027. The company is pivoting its AATD program to a GalNAc-conjugated construct after its KRRO-110 single dose failed to reach projected protein levels, and has nominated KRRO-121 for hyperammonemia, with clinical trials anticipated in H2 2026. Despite positive functional protein observation, the market reacted negatively, with Korro stock declining 4.21% on the news.
Korro Bio Reports Increased Losses Amid Strategic Developments
Korro Bio, Inc. (KRRO) reported increased net losses of $67.2 million for the nine months ending September 30, 2025, up from $62.4 million in the prior year, despite recognizing $5.1 million in collaboration revenue. The clinical-stage biopharmaceutical company is actively advancing its RNA editing technology and KRRO-110 program, and is focused on securing additional funding to support its research and development goals.
Clear Street Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation
Clear Street has initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Buy recommendation. Analysts project a significant upside of 162.70% from its current price, with an average one-year target of $95.75/share. Despite a projected decrease in annual revenue, fund sentiment indicates a bullish outlook, with institutions holding over 10 million shares.
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?
The article analyzes Korro Bio's cash burn rate and cash runway, concluding that the company has approximately 16 months of cash based on its US$74m annual burn and US$96m cash reserves. Despite being unprofitable, Korro Bio's reduced cash burn and ability to raise additional capital, even with some shareholder dilution, suggest a less problematic financial situation. The author advises shareholders to monitor the cash burn over time.
Korro Bio stock price target lowered to $147 at Raymond James
Raymond James has lowered its price target for Korro Bio Inc. (NASDAQ:KRRO) to $147 from $153, while maintaining a Strong Buy rating. This decision follows the company's Q2 2025 earnings report and positive outlook on its lead asset KRRO-110 for alpha-1 antitrypsin deficiency (AATD), which recently received orphan drug designation from the European Medicines Agency. Despite current unprofitability, Korro Bio boasts strong liquidity and positive trial results for KRRO-110, with an interim readout expected in late 2025.
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright
H.C. Wainwright has lowered its price target for Korro Bio (KRRO) to $53 from $130 while maintaining a Buy rating on the shares. This adjustment follows Korro Bio's Q1 results and a 20% workforce reduction aimed at extending the company's cash runway into 2027. The firm believes Korro Bio's catalysts are on track but has modified its model due to the increasing competition in the alpha-1 antitrypsin deficiency landscape.
4 more biotechs cut staff amid market tumult
Four biotechnology companies — Vor Bio, Korro Bio, Insitro, and Rallybio — have announced significant workforce reductions, with Vor Bio cutting 95% of its staff and discontinuing clinical operations amidst financial market difficulties. This wave of layoffs reflects a broader struggle in the biotech sector, where market volatility, slowed dealmaking, and scarce IPOs are forcing companies to cut costs and find new funding strategies. Overall, 95 drugmakers have reduced staff this year, indicating a challenging period for the industry.
FDA names Scott Steele acting head of CBER after Marks’ ouster
Scott Steele has been appointed as the acting director of the FDA's Center for Biologics Evaluation and Research (CBER) following the departure of Peter Marks. Steele previously served as senior adviser for translational science in CBER’s Office of Center Director. This appointment comes amidst other leadership changes at the FDA, including unfilled vacancies for the director of the Office of New Drugs at CDER and the FDA Chief Medical Officer, whose former occupants resigned rather than accept demotions.
